Alivexis Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • Series D

  • Latest Deal Amount
  • $5.1M

  • Investors
  • 19

Alivexis General Information

Description

Developer of a drug discovery platform designed to accelerate the biotechnological research of new medicines. The company's platforms are prepared with computational drug discovery expertise and biology insights and focus on the rapid design and generation of small molecule clinical candidates for a range of high-value disease targets, enabling healthcare professionals to focus on the efficient delivery of medicines for patients and their families with unmet medical needs.

Contact Information

Formerly Known As
Modulus
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1 Broadway
  • 14th Floor
  • Cambridge, MA 02142
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 1 Broadway
  • 14th Floor
  • Cambridge, MA 02142
  • United States

Alivexis Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alivexis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series D) 07-Jan-2025 $5.1M Completed Clinical Trials - General
6. Accelerator/Incubator Completed Clinical Trials - General
5. Accelerator/Incubator 06-Apr-2023 Completed Clinical Trials - General
4. Later Stage VC (Series C) 01-Mar-2022 Completed Clinical Trials - General
3. Early Stage VC (Series B) 13-May-2020 Completed Clinical Trials - General
2. Early Stage VC (Series A) 09-Aug-2018 $7.17M $10.8M Completed Clinical Trials - General
1. Seed Round 23-Aug-2017 $3.63M $3.63M Completed Startup
To view Alivexis’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Alivexis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a drug discovery platform designed to accelerate the biotechnological research of new medicines. The compan
Drug Discovery
Cambridge, MA
12 As of 2026

Maastricht, Netherlands
 

Santa Cruz, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alivexis Competitors (41)

One of Alivexis’s 41 competitors is Cristal Therapeutics, a Venture Capital-Backed company based in Maastricht, Netherlands.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cristal Therapeutics Venture Capital-Backed Maastricht, Netherlands
MicroCures Venture Capital-Backed Santa Cruz, CA
PeptiDream Formerly VC-backed Kawasaki, Japan
Sangamo Therapeutics Formerly VC-backed Richmond, CA
Personalis Formerly VC-backed Fremont, CA
You’re viewing 5 of 41 competitors. Get the full list »

Alivexis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alivexis Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds
JIC Venture Growth Investments Venture Capital Minority
J-Startup Accelerator/Incubator
Green Co-Invest Investment Asset Manager Minority
Heights Capital Growth/Expansion Minority
StartX (US) Accelerator/Incubator Minority
You’re viewing 5 of 19 investors. Get the full list »

Alivexis Investments (1)

Alivexis’s most recent deal was a Corporate Asset Purchase with Melodia Therapeutics (Commercial Rights for Drug Mdi-0151) for . The deal was made on 21-Jun-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Melodia Therapeutics (Commercial Rights for Drug Mdi-0151) 21-Jun-2024 Corporate Asset Purchase Buildings and Property
To view Alivexis’s complete investments history, request access »

Alivexis FAQs

  • When was Alivexis founded?

    Alivexis was founded in 2017.

  • Where is Alivexis headquartered?

    Alivexis is headquartered in Cambridge, MA.

  • What is the size of Alivexis?

    Alivexis has 12 total employees.

  • What industry is Alivexis in?

    Alivexis’s primary industry is Drug Discovery.

  • Is Alivexis a private or public company?

    Alivexis is a Private company.

  • What is Alivexis’s current revenue?

    The current revenue for Alivexis is .

  • How much funding has Alivexis raised over time?

    Alivexis has raised $61.6M.

  • Who are Alivexis’s investors?

    JIC Venture Growth Investments, J-Startup, Green Co-Invest Investment, Heights Capital, and StartX (US) are 5 of 19 investors who have invested in Alivexis.

  • Who are Alivexis’s competitors?

    Cristal Therapeutics, MicroCures, PeptiDream, Sangamo Therapeutics, and Personalis are some of the 41 competitors of Alivexis.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process